Skip to main content
Fig. 1 | BMC Cardiovascular Disorders

Fig. 1

From: Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Fig. 1

Lipid and lipoprotein associations of a PCSK9 gene-centric score (GS) compared to placebo-controlled randomized trials of therapeutic inhibition of PCSK9. Footnote: Effect estimates are presented as mean differences, with 95% confidence interval (CI). Trial estimates are presented as percentage change from baseline (during 6 months of follow-up), and GS estimates scaled to a 1 mmol/L lower LDL-C (mmol/L). Results are pooled using a fixed effect model. Trial estimates are based on the systematic review by Schmidt et al 2017 [6, 17]

Back to article page